Supermax (7106) Fundamentals 2026 — Revenue Analysis | SniperIQ
Supermax (7106) is a MY-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of RM825M, trading at RM0.27 on the KLS. This SniperIQ fundamentals page covers Supermax's valuation, profitability (net margin -40.0%), revenue (RM782M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Supermax's market cap?
Supermax (7106) has a market capitalization of approximately RM825M, trading at RM0.27 on the KLS. Market cap moves with the live share price.
What is Supermax's P/E ratio?
Supermax's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Supermax?
Supermax runs a net profit margin of -40.0%, a gross margin of 60.2%, and an operating margin of -49.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Supermax generate?
Supermax reported revenue of RM782M for fiscal year 2025, with net income of -RM160M and earnings per share (EPS) of -0.052. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Supermax pay a dividend?
Supermax does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Supermax financially healthy?
Supermax carries a debt-to-equity ratio of 0.04x and a current ratio of 2.95x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Supermax a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Supermax (7106) the key facts are: market cap RM825M, revenue RM782M, 52-week range 0.25-0.605. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Supermax's full fundamentals live
Get Supermax's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.